These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7738422)

  • 21. Hypercoagulable states: molecular genetics to clinical practice.
    Schafer AI
    Lancet; 1994 Dec 24-31; 344(8939-8940):1739-42. PubMed ID: 7997003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V.
    Greengard JS; Eichinger S; Griffin JH; Bauer KA
    N Engl J Med; 1994 Dec; 331(23):1559-62. PubMed ID: 7969326
    [No Abstract]   [Full Text] [Related]  

  • 23. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.
    Weitz IC; Israel VK; Liebman HA
    Cancer; 1997 May; 79(10):2024-7. PubMed ID: 9149031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives--a short review.
    Jespersen J
    Eur J Contracept Reprod Health Care; 1996; 1(1):3-11. PubMed ID: 9678132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombophilia: the discovery of activated protein C resistance.
    Dahlbäck B
    Adv Genet; 1995; 33():135-75. PubMed ID: 7484452
    [No Abstract]   [Full Text] [Related]  

  • 26. [Resistance to activated protein C. The most common cause of familial thrombophilia].
    Larsen TB; Ravn HB; Lassen JF; Lund ED; Brandslund I
    Ugeskr Laeger; 1996 Nov; 158(46):6584-8. PubMed ID: 8966822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Screening in activated protein C resistance].
    Bergmann F
    Internist (Berl); 1997 Sep; 38(9):864. PubMed ID: 9410836
    [No Abstract]   [Full Text] [Related]  

  • 28. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
    Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
    Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Activated C protein resistance: laboratory study and prevalence of the defect in the Chilean population].
    Pereira J; Quiroga T; Goycoolea M; Muñoz B; Hidalgo P; Kaltwasser G; Mezzano D
    Rev Med Chil; 1996 Jun; 124(6):663-8. PubMed ID: 9041721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factor V Leiden and thrombophilia.
    Simioni P; Scudeller A; Girolami A
    N Engl J Med; 1995 May; 332(20):1382. PubMed ID: 7715653
    [No Abstract]   [Full Text] [Related]  

  • 31. [Retinal vein occlusion and resistance to activated protein C].
    Scat Y; Morin Y; Morel C; Haut J
    J Fr Ophtalmol; 1995; 18(12):758-62. PubMed ID: 8745708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical findings in individuals with the factor V Leiden mutation].
    Matýsková M; Vorlová Z; Hrachovinová I; Buliková A; Zavrelová J; Slechtová M
    Vnitr Lek; 1997 May; 43(5):298-301. PubMed ID: 9601852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [APC resistance and blood coagulation factor V mutation in Finnish thrombotic patients].
    Hakala L; Vahtera E; Krusius T; Rasi V
    Duodecim; 1995; 111(22):2143-51. PubMed ID: 9841174
    [No Abstract]   [Full Text] [Related]  

  • 34. Factor V Leiden: an overview.
    Shaw DM
    Clin Lab Sci; 2006; 19(4):218-21. PubMed ID: 17181126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to activated protein C due to factor V R506Q mutation as a cause of venous thrombosis.
    Dahlbäck B
    Rev Invest Clin; 1997 May; 49 Suppl 1():3-5. PubMed ID: 9291738
    [No Abstract]   [Full Text] [Related]  

  • 36. [Factor V Leiden and thrombophilia].
    Mahassen P; Dicato M
    Bull Soc Sci Med Grand Duche Luxemb; 1997; 134(2):17-22. PubMed ID: 9534269
    [No Abstract]   [Full Text] [Related]  

  • 37. Ischemic colitis and acquired resistance to activated protein C in a woman using oral contraceptives.
    Mann DE; Kessel ER; Mullins DL; Lottenberg R
    Am J Gastroenterol; 1998 Oct; 93(10):1960-2. PubMed ID: 9772065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Changes in hemostasis system in patients with hereditary thrombophilia caused by mutation of blood coagulation factor V ( factor V Leiden)].
    Papaian LP; Kobilianskaia VA; Sheĭdina AM; Baranovskaia SS; Sirotkina OV; Kargin VD; Saltykova NB; Beliazo OE; Golovina OG; Papaian KA; Tarkovskaia LR
    Ter Arkh; 2001; 73(7):47-51. PubMed ID: 11523408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inherited homozygous resistance to activated protein C.
    Villa P; Aznar J; Jorquera J; Mira Y; Vayá A; Fernández MA
    Thromb Haemost; 1995 Aug; 74(2):794-5. PubMed ID: 8585025
    [No Abstract]   [Full Text] [Related]  

  • 40. [The significance of APC resistance (activated protein C) for clinical practice].
    Lämmle B; Demarmels Biasiutti F; Wuillemin WA; Stucki B; Furlan M
    Praxis (Bern 1994); 1997 Jan; 86(5):154-61. PubMed ID: 9064734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.